natgillin/translations-raw huggingface dataset:
If you have difficulty swallowing the whole tablet, talk to your doctor about other ways to take Adempas. 
Če ne morete požirati celih tablet, se z zdravnikom pogovorite o drugih načinih jemanja zdravila Adempas.
The maximum total daily dose is 7.5 mg i.e., 2.5 mg 3 times daily. 
Največji dnevni odmerek je 7,5 mg, tj. 2,5 mg trikrat na dan.
Concomitant treatment of riociguat and warfarin did not alter prothrombin time induced by the anticoagulant. 
Sočasno zdravljenje z riociguatom in varfarinom ni vplivalo na spremembo protrombinskega časa, doseženega z antikoagulantom.
- if you have increased pressure in your pulmonary circulation associated with scarring of the lungs, of unknown cause (idiopathic pulmonary pneumonia). 
- če imate zvišan tlak v pljučnem krvnem obtoku, povezan z brazgotinjenjem pljuč neznanega vzroka (idiopatsko pljučnico).
In chronic thromboembolic pulmonary hypertension, pulmonary endarterectomy is the treatment of choice as it is a potentially curative option. 
Pri kronični trombembolični pljučni hipertenziji je pljučna endarteriektomija metoda izbora za zdravljenje, saj je potencialno kurativna.
If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. 
Če ste noseči ali dojite, menite, da bi lahko bili noseči ali načrtujete zanositev, se posvetujte z zdravnikom ali farmacevtom, preden vzamete to zdravilo.
Therefore, patients are advised to stop smoking (see section 4.2). 
Zato je treba bolnikom svetovati, da prenehajo kaditi (glejte poglavje 4.2).
Cobicistat, ritonavir, atazanavir and darunavir are additionally classified as CYP3A inhibitors. 
Kobicistat, ritonavir, atazanavir in darunavir so dodatno opredeljeni kot zaviralci CYP3A.
Effects observed in repeat-dose toxicity studies were mainly due to the exaggerated pharmacodynamic activity of riociguat (haemodynamic and smooth muscle relaxing effects). 
Učinki, ki so jih opazili v študijah ponavljajočih odmerkov, so bili posledica predvsem poudarjene farmakodinamične aktivnosti riociguata (hemodinamski učinki in sprostitev gladkih mišic).
Corresponding values for the main metabolite were higher in subjects with renal impairment compared to healthy subjects. 
Ustrezne vrednosti za glavni presnovek so bile večje pri osebah z ledvično okvaro v primerjavi z zdravimi osebami.
Should signs of pulmonary oedema occur, the possibility of associated PVOD should be considered and treatment with riociguat should be discontinued. 
Če se pojavijo znaki pljučnega edema, je treba pomisliti na možnost pridružene pljučne venookluzivne bolezni in zdravljenje z riociguatom prekiniti.
What you need to know before you take Adempas 
Kaj morate vedeti, preden boste vzeli zdravilo Adempas
What Adempas is and what it is used for 
Kaj je zdravilo Adempas in za kaj ga uporabljamo
These findings were in accordance with improvements in additional haemodynamic parameters (see table 5). 
Ti izsledki so bili v skladu z izboljšanjem drugih hemodinamskih parametrov (glejte preglednico 5).
In elderly patients (65 years or older) there is a higher risk of hypotension and therefore particular care should be exercised during individual dose titration (see section 5.2). 
Pri starejših bolnikih (starih 65 let ali več) obstaja večje tveganje za hipotenzijo, zato je pri titriranju odmerka potrebna posebna previdnost (glejte poglavje 5.2).
Riociguat must not be used in patients with a systolic blood pressure below 95 mmHg (see section 4.3). 
Riociguata se ne sme uporabljati pri bolnikih s sistoličnim krvnim tlakom nižjim od 95 mm Hg (glejte poglavje 4.3).
There was no evidence of a favourable clinical effect of the combination in the population studied. 
Koristni klinični učinki omenjene kombinacije zdravil v preučevani populaciji niso bili ugotovljeni.
Adempas is available in different strengths and by checking your blood pressure regularly at the beginning of your treatment, your doctor will ensure that you are taking the appropriate dose. 
Zdravilo Adempas je na voljo v različnih jakostih, zato bo zdravnik z rednim merjenjem vašega krvnega tlaka na začetku zdravljenja določil ustrezen odmerek.
If you forget to take Adempas 
Če ste pozabili vzeti zdravilo Adempas
Adempas is a film-coated tablet: 
Zdravilo Adempas je filmsko obložena tableta:
• acute bleeding from the lungs (pulmonary haemorrhage) may result in coughing up blood, cases with fatal outcomes were observed (uncommon side effect, may affect up to 1 in 100 people). 
• akutna krvavitev v pljučih (pulmonalna krvavitev) lahko povzroči izkašljevanje krvi, opazili so primere s smrtnim izidom (občasni neželeni učinek, ki se lahko pojavi pri največ 1 od
Intake with food reduced riociguat AUC slightly, Cmax was reduced by 35%. 
Jemanje s hrano blago zmanjša AUC riociguata; Cmax se je zmanjšal za 35 %.
• In patients on stable doses of Adempas, the initiation of strong multi pathway CYP and P-gp/BCRP inhibitors is not recommended as no dosage recommendation can be given due to limited data. 
• Pri bolnikih na stabilnih odmerkih zdravila Adempas se ne priporoča uvedba močnih zaviralcev več presnovnih poti CYP in P-gp/BCRP, ker zaradi omejenih podatkov ni mogoče dati nobenega priporočila.
If you have been told by a doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine. 
Če vam je zdravnik povedal, da ne prenašate nekaterih sladkorjev, se pred uporabo tega zdravila posvetujte z zdravnikom.
Pulmonary vasodilators may significantly worsen the cardiovascular status of patients with pulmonary veno-occlusive disease (PVOD). 
Pljučni vazodilatatorji lahko močno poslabšajo kardiovaskularno stanje bolnikov s pljučno venookluzivno boleznijo (PVOD - pulmonary veno-occlusive disease).
In pulmonary hypertension patients there is increased likelihood for respiratory tract bleeding, particularly among patients receiving anticoagulation therapy. 
Pri bolnikih s pljučno hipertenzijo je večja verjetnost krvavitev v dihalih, predvsem pri bolnikih, ki se zdravijo z antikoagulanti.
Therefore, drug-drug interactions by inhibition of CYP1A1 could result in increased riociguat exposure, especially in smokers (see section 5.2). 
Zato lahko medsebojno delovanje zdravil, ki zavirajo CYP1A1 poveča izpostavljenost riociguatu, predvsem pri kadilcih (glejte poglavje 5.1).
This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially “sodium free”. 
To zdravilo vsebuje manj kot 1 mmol (23 mg) natrija na odmerek, kar v bistvu pomeni »brez natrija«.
Do not take Adempas: - if you are taking certain medicines called PDE5 inhibitors (e.g. sildenafil, tadalafil, vardenafil). 
Ne jemljite zdravila Adempas: - če jemljete določena zdravila, imenovana zaviralci PDE-5 (npr. sildenafil, tadalafil, vardenafil).
Strong CYP1A1 inhibitors should be used with caution (see section 4.4). 
Močne zaviralce CYP1A1 je treba uporabljati previdno (glejte poglavje 4.4).
For the transition from PDE5 inhibitors to riociguat, median treatment-free time for sildenafil was 1 day and for tadalafil 3 days. 
Ob prehodu z zaviralcev PDE5 na riociguat je bil mediani čas brez zdravljenja 1 dan za sildenafil in 3 dni za tadalafil.
The recommended starting dose is 1 mg three times daily for 2 weeks. 
Priporočeni začetni odmerek je 1 mg trikrat na dan 2 tedna.
There is no clinical experience with riociguat in patients with elevated liver aminotransferases (> 3 x Upper Limit of Normal (ULN)) or with elevated direct bilirubin (> 2 x ULN) prior to initiation of treatment; riociguat is not recommended in these patients. 
Ker ni kliničnih izkušenj z riociguatom pri bolnikih s povečanimi vrednostmi jetrnih aminotransferaz (> 3-kratna zgornja meja normalne vrednosti (ULN - Upper Limit of Normal)) ali s povečanimi vrednostmi direktnega bilirubina (> 2 x ULN) pred začetkom zdravljenja, se uporaba riociguata pri teh bolnikih ne priporoča.
Therefore, administration of riociguat to such patients is not recommended. 
Zato se uporabe riociguata ne priporoča pri teh bolnikih.
In the long term extension part of this study (non controlled) the concomitant use of sildenafil and riociguat resulted in a high rate of discontinuation, predominately due to hypotension. 
V dolgotrajnem podaljšanju študije (brez primerjalne skupine) je sočasna uporaba sildenafila in riociguata povzročila pogostejše prekinitve zdravljenja, predvsem zaradi hipotenzije.
Other medicines for high blood pressure in the lung vessels (PAH), such as bosentan and iloprost, can be used with Adempas, but you should still tell your doctor. 
Sočasno lahko uporabljate druga zdravila za zdravljenje visokega krvnega tlaka v pljučnih žilah (PAH), npr. bosentan in iloprost, vendar morate o tem obvestiti zdravnika.
Transitioning between phosphodiesterase-5 (PDE5) inhibitors and riociguat Sildenafil must be discontinued at least 24 hours prior to administration of riociguat. 
Prehod med zaviralci fosfodiesteraze-5 (PDE5) in riociguatom Z uporabo sildenafila je treba prenehati vsaj 24 ur pred uporabo riociguata.
Your doctor will increase the dose every 2 weeks to a maximum of 2.5 mg 3 times a day (maximum daily dose of 7.5 mg) unless you experience any side effects or very low blood pressure. 
Zdravnik bo povečal odmerek vsaka 2 tedna do največ 2,5 mg, trikrat na dan (največji dnevni odmerek 7,5 mg), razen če se vam bo pojavil kakšen neželeni učinek ali zelo nizek krvni tlak.
Improvement in exercise capacity was accompanied by consistent improvement in multiple clinicallyrelevant secondary endpoints. 
Izboljšanje telesne zmogljivosti je spremljalo dosledno izboljšanje številnih klinično pomembnih sekundarnih opazovanih ciljev.
According to standard medical practice, expert assessment of operability should be done prior to treatment with riociguat. 
Glede na običajno klinično prakso, je treba strokovno oceno o primernosti kirurškega posega pri bolniku opraviti pred zdravljenjem z riociguatom.
The most commonly reported adverse reactions, occurring in ≥10% of patients under Adempas treatment (up to 2.5 mg three times daily), were headache, dizziness, dyspepsia, peripheral oedema, nausea, diarrhoea and vomiting. 
Neželeni učinki, o katerih so poročali najpogosteje in so se pojavili pri ≥ 10 % bolnikov, zdravljenih z zdravilom Adempas (do 2,5 mg trikrat na dan), so bili glavobol, omotica, dispepsija, periferni edem, navzea, driska in bruhanje.
42 film-coated tablets 84 film-coated tablets 90 film-coated tablets 294 film-coated tablets 
42 filmsko obloženih tablet 84 filmsko obloženih tablet 90 filmsko obloženih tablet 294 filmsko obloženih tablet
The safety profile of Adempas in patients with CTEPH and PAH appeared to be similar, therefore adverse reactions identified from placebo controlled 12 and 16 weeks clinical studies are presented as pooled frequency in the table listed below (see table 1). 
Profil varnosti za zdravilo Adempas pri bolnikih s CTEPH in PAH je podoben, zato so neželeni učinki, ki so jih ugotovili v s placebom nadzorovanih 12- in 16-tedenskih kliničnih študijah, predstavljeni združeno v spodnji preglednici pogostnosti (glejte preglednico 1).
Overall, the safety profile observed in the study was comparable with that observed in the pivotal trials, with no serious adverse events reported during the transition period. 
Na splošno je varnostni profil, ki so ga opazili v študiji, primerljiv s tistim, ki so ga opazili v ključnih preskušanjih.
In nonsmoking individuals with mild (creatinine clearance 80-50 mL/min), moderate (creatinine clearance <50-30 mL/min) or severe (creatinine clearance <30 mL/min) renal impairment, riociguat plasma concentrations (AUC) were increased by 53%, 139% or 54%, respectively. 
Pri nekadilcih z blago (očistek kreatinina 80 - 50 ml/min), zmerno (očistek kreatinina < 50 - 30 ml/min) ali hudo (očistek kreatinina < 30 ml/min) ledvično okvaro so se koncentracije riociguata v plazmi (AUC) povečale za 53 %, 139 % oz. 54 %.
Total riociguat (parent compound and metabolites) is excreted via both renal (33-45%) and biliary/faecal routes (48-59%). 
Celokupni riociguat (izhodna spojina in presnovki) se izloča skozi ledvice (33 - 45 %) in z blatom/žolčem (48 - 59 %).
Preclinical studies in animal models showed additive systemic blood pressure lowering effect when riociguat was combined with either sildenafil or vardenafil. 
Zaviralci PDE5 Predklinične študije na živalskih modelih so pokazale aditiven učinek na znižanje sistemskega krvnega tlaka, pri uporabi riociguata v kombinaciji s sildenafilom ali vardenafilom.
Serious bleeding occurred in 2.4% (12/490) of patients taking riociguat compared to 0/214 of placebo patients. 
Resne krvavitve so se pojavile pri 2,4 % (12/490) bolnikov, ki so jemali riociguat, v primerjavi z 0/214 bolnikov, ki so jemali placebo.
The established individual dose should be maintained unless signs and symptoms of hypotension occur. 
S titriranjem ugotovljeni odmerek za posameznega bolnika je treba vzdrževati, razen če se pojavijo znaki in simptomi hipotenzije.
More patients taking riociguat died (11% vs. 4%) and had serious adverse events (37% vs. 23%) during the main phase. 
Med osnovno fazo je več bolnikov, ki so jemali riociguat, umrlo (11 % v primerjavi s 4 %) in imelo resne neželene učinke (37 % v primerjavi s 23 %).
Breast-feeding should be discontinued during treatment with this medicinal product. 
Med zdravljenjem s tem zdravilom je treba prenehati z dojenjem.
Paediatric population No studies have been conducted to investigate the pharmacokinetics of riociguat in paediatric patients. 
Pediatrična populacija Študij farmakokinetike riociguata pri pediatričnih bolnikih niso izvedli.
Improvement in exercise capacity was accompanied by improvement in multiple clinically relevant secondary endpoints. 
Izboljšanje telesne zmogljivosti je spremljalo izboljšanje številnih klinično pomembnih sekundarnih opazovanih ciljev.
In some PAH patients, an adequate response on the 6-minute walk distance (6MWD) may be reached at a dose of 1.5 mg three times a day (see section 5.1). 
Pri nekaterih bolnikih s PAH se lahko doseže ustrezni odziv pri merjenju prehojene razdalje v testu šestminutne hoje (6MWD - 6-minute walk distance) že z odmerkom 1,5 mg trikrat na dan (glejte poglavje 5.1).
Therefore, female patients at potential risk of pregnancy must use an effective method of contraception. 
Ženske, pri katerih obstaja možnost, da zanosijo, morajo uporabljati učinkovito metodo kontracepcije.
However, if you are prone to having low blood pressure (hypotension), you should not switch from taking Adempas with food to taking Adempas without food because it may affect how you react to this medicine. 
Če ste nagnjeni k nizkemu krvnemu tlaku (hipotenzija), ne spreminjajte načina jemanja zdravila Adempas, tako da ga enkrat vzamete s hrano, drugič brez nje, saj to lahko vpliva na vaš odziv na zdravljenje z zdravilom Adempas.
Dose should be increased by 0.5 mg three times daily every two weeks to a maximum of 2.5 mg three times daily, if systolic blood pressure is ≥95 mmHg and the patient has no signs or symptoms of hypotension. 
Odmerek je treba povečevati vsaka dva tedna za 0,5 mg trikrat na dan do največ 2,5 mg trikrat na dan, če je sistolični krvni tlak ≥ 95 mm Hg in če bolnik nima znakov ali simptomov hipotenzije.
Common: may affect up to 1 in 10 people - inflammation of the stomach (gastritis) - inflammation in the digestive system (gastroenteritis) - reduction of red blood cells (anaemia) seen as pale skin, weakness or breathlessness - awareness of an irregular, hard, or rapid heartbeat (palpitation) - low blood pressure (hypotension) - nose bleed (epistaxis) - difficulty breathing through your nose (nasal congestion) - pain in the stomach, intestine or abdomen (gastrointestinal and abdominal pain) - heartburn (gastro-oesophageal reflux disease) - difficulty in swallowing (dysphagia) - constipation - bloating (abdominal distension) 
Pogosti: pojavijo se lahko pri največ 1 od 10 bolnikov - vnetje v želodcu (gastritis) - vnetje v prebavilih (gastrenteritis) - zmanjšanje števila rdečih krvnih celic (anemija), kar se kaže kot bleda koža, šibkost ali zasoplost - občutek nerednega, močnega ali hitrega srčnega utripa (palpitacije) - nizek krvni tlak (hipotenzija) - krvavitev iz nosu (epistaksa) - oteženo dihanje skozi nos (kongestija nosne sluznice) - bolečine v želodcu, prebavilih ali trebuhu (gastrointestinalne in abdominalne bolečine) - zgaga (gastroezofagealna refluksna bolezen) - težave pri požiranju (disfagija) - zaprtost - napenjanje (abdominalna distenzija)
For patients who are unable to swallow whole tablets, Adempas tablets may be crushed and mixed with water or soft foods, such as apple sauce, immediately prior to use and administered orally (see section 5.2). 
Za bolnike, ki ne morejo požirati celih tablet, se lahko tablete zdravila Adempas tik pred uporabo zdrobijo in zmešajo z vodo ali mehko hrano, kot je na primer jabolčna čežana, ter dajo peroralno (glejte poglavje 5.2).
If you have severe liver problems (Child Pugh C), do not take Adempas. 
Če imate hudo jetrno okvaro (Child Pugh C), ne jemljite zdravila Adempas.
Riociguat restores the NO-sGC-cGMP pathway and leads to increased generation of cGMP. 
Riociguat ponovno vzpostavi pot NO-sGC-cGMP in poveča nastajanje cGMP.
Serious haemoptysis occurred in 1% (5/490) patients taking riociguat compared to 0/214 patients taking placebo, including one event with fatal outcome. 
Resna hemoptiza se je pojavila pri 1 % (5/490) bolnikov, ki so jemali riociguat, v primerjavi z 0/214 bolnikov, ki so jemali placebo, vključno z enim smrtnim izidom.
Antacids should be taken at least 2 hours before, or 1 hour after riociguat. 
Antacide je treba vzeti najmanj 2 uri pred oziroma 1 uro po zaužitju riociguata.
Bosentan, reported to be a moderate inducer of CYP3A4, led to a decrease of riociguat steady-state plasma concentrations in PAH patients by 27% (see sections 4.1 and 5.1). 
Bosentan, za katerega poročajo, da je zmerni induktor CYP3A4, je v stanju dinamičnega ravnovesja pri bolnikih s PAH zmanjšal koncentracijo riociguata v plazmi za 27 % (glejte poglavji 4.1 in 5.1).
RESPITE was a 24-week, uncontrolled study to investigate switching from PDE5 inhibitors to riociguat, in 61 adult PAH patients on stable PDE5 inhibitors. 
V nenadzorovani, 24-tedenski študiji RESPITE so preučevali prehod z zaviralcev PDE5 na riociguat pri 61 odraslih bolnikih s PAH, ki so bili stabilni na zdravljenju z zaviralci PDE5.
Medicinal products strongly inhibiting P-gp/BCRP such as the immuno-suppressive cyclosporine A, should be used with caution (see sections 4.4 and 5.2). 
Zdravila, ki močno zavirajo P-gp/BCRP, kot je imunosupresiv ciklosporin A, je treba uporabljati previdno (glejte poglavji 4.4 in 5.2).
Patients with mild and moderate renal impairment (creatinine clearance <80 - 30 mL/min) showed a higher exposure to this medicinal product (see section 5.2). 
Pri bolnikih z blago in zmerno ledvično okvaro (očistek kreatinina < 80 - 30 ml/min) je bila izpostavljenost temu zdravilu večja (glejte poglavje 5.2).
Co-treatment of medicinal products increasing the upper gastro intestinal pH may lead to lower oral bioavailability. 
Sočasno zdravljenje z zdravili, ki zvišujejo pH vrednost v zgornjih prebavilih, lahko povzroči manjšo peroralno biološko uporabnost.
If you stop taking Adempas 
Če ste prenehali jemati zdravilo Adempas
Concomitant administration of 400 mg once daily ketoconazole led to a 150% (range up to 370%) increase in riociguat mean AUC and a 46% increase in mean Cmax. 
Sočasna uporaba s 400 mg ketokonazola enkrat na dan je povzročila 150 % (razpon do 370 %) povečanje povprečne AUC in 46 % povečanje povprečne Cmax riociguata.
Therefore, clinically relevant drug-drug interactions with co-treatment which are significantly cleared by CYP1A1-mediated biotransformation, such as erlotinib or granisetron cannot be ruled out. 
Zato klinično pomembnega medsebojnega delovanja s sočasnim zdravljenjem z zdravili, ki se izločajo predvsem preko presnove s CYP1A1, kot sta erlotinib ali granisetron, ni mogoče izključiti.
If systolic blood pressure falls below 95 mmHg, the dose should be maintained provided the patient does not show any signs or symptoms of hypotension. 
Če se sistolični krvni tlak zniža pod 95 mm Hg, je treba odmerek vzdrževati, če bolnik nima znakov ali simptomov hipotenzije.
Concomitant administration of HAART combinations led to an increase in riociguat mean AUC of up to about 160% and to an approximate 20% increase in mean Cmax. 
Sočasna uporaba s HAART kombinacijami je povzročila do 160 % povečanje povprečne AUC in približno 20 % povečanje povprečne Cmax riociguata.
cellulose microcrystalline crospovidone (type B) hypromellose 5 cP magnesium stearate lactose monohydrate sodium laurilsulfate 
mikrokristalna celuloza krospovidon (tip B) hipromeloza 5 cP magnezijev stearat laktoza monohidrat natrijev lavrilsulfat
Pulmonary hypertension is associated with endothelial dysfunction, impaired synthesis of NO and insufficient stimulation of the NO-sGC-cGMP pathway. 
Pljučna hipertenzija je povezana s poškodbo endotelija, moteno sintezo dušikovega oksida in nezadostnim spodbujanjem poti NO-sGC-cGMP.
Women of childbearing potential / Contraception 
Ženske v rodni dobi/ kontracepcija
You should tell your doctor if you start or stop smoking during treatment with this medicine. 
Obvestite zdravnika, če med zdravljenjem s tem zdravilom začnete ali prenehate kaditi.
Therefore use of Adempas is not recommended in these patients (see section 4.4). 
Zato se uporaba zdravila Adempas pri teh bolnikih ne priporoča (glejte poglavje 4.4).
Before prescribing riociguat, physicians should carefully consider whether patients with certain underlying conditions, could be adversely affected by vasodilatory effects (e.g. patients on antihypertensive therapy or with resting hypotension, hypovolaemia, severe left ventricular outflow obstruction or autonomic dysfunction). 
Preden zdravnik predpiše riociguat, mora skrbno oceniti, ali bi lahko vazodilatacijski učinki riociguata vplivali na nekatera obstoječa stanja bolnika (npr. bolniki, ki uporabljajo antihipertenzivna zdravila ali hipotenzija med mirovanjem, hipovolemija, huda obstrukcija izstisa iz levega prekata ali avtonomna okvara).
In case of respiratory tract bleeding, the prescriber should regularly assess the benefitrisk of treatment continuation. 
V primeru krvavitve v dihalih mora zdravnik redno ocenjevati korist nadaljevanja zdravljenja v primerjavi s tveganjem.
What Adempas looks like and contents of the pack 
Izgled zdravila Adempas in vsebina pakiranja
In pulmonary arterial hypertension, studies with riociguat have been mainly performed in forms related to idiopathic or heritable PAH and PAH associated with connective tissue disease. 
Pri bolnikih s pljučno arterijsko hipertenzijo so študije z riociguatom izvedli predvsem pri idiopatski ali dedni PAH in PAH, povezani z boleznijo veziva.
In rats, an increased rate of cardiac malformation was observed as well as a reduced gestation rate due to early resorption at maternal systemic exposure of about 7-fold of human exposure (2.5 mg three times daily). 
Pri podganah so opazili pogostejše deformacije srca in manj pogoste gestacije zaradi hitre resorpcije pri sistemski izpostavljenosti matere, ki je bila približno 7-krat večja od izpostavljenosti pri ljudeh (2,5 mg trikrat na dan).
Nervous system disorders Dizziness, Headache 
Bolezni živčevja omotica, glavobol
Therefore co-administration of Adempas with nitrates or nitric oxide donors (such as amyl nitrite) in any form, including recreational drugs called ‘poppers', is contraindicated (see section 4.3). 
Zato je sočasna uporaba zdravila Adempas z nitrati ali donorji dušikovega oksida (npr. amilnitrit) v kakršni koli obliki, vključno z rekreacijskimi drogami, t. i. »poppers«, kontraindicirana (glejte poglavje 4.3).
There are no data from the use of riociguat in pregnant women. 
Podatkov o uporabi riociguata pri nosečnicah ni na voljo.
Riociguat is a stimulator of soluble guanylate cyclase (sGC), an enzyme in the cardiopulmonary system and the receptor for nitric oxide (NO). 
Riociguat je spodbujevalec topne gvanilat-ciklaze (sGC - soluble guanylate cyclase), encima v kardiopulmonarnem sistemu in receptorja za dušikov oksid (NO - nitric oxide).